ZEAL +9% on phase-3 hypoglycemia results: https://globenewswire.com/news-release/2018/09/18/1572374/0/en/Zealand-Pharma-achieves-primary-and-key-secondary-endpoints-in-pivotal-Phase-3-trial-with-dasiglucagon-for-severe-hypoglycemia.html